Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000672901 | SCV000798053 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2018-02-21 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV001075017 | SCV001240627 | pathogenic | Retinal dystrophy | 2018-02-15 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001092379 | SCV001248860 | pathogenic | not provided | 2018-09-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001092379 | SCV001584156 | pathogenic | not provided | 2023-05-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 556842). Disruption of this splice site has been observed in individuals with USH2A-related conditions (PMID: 17405132, 28559085, 29151245, 31054281). This variant is present in population databases (rs748961218, gnomAD 0.0009%). This sequence change affects an acceptor splice site in intron 12 of the USH2A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). |
Equipe Genetique des Anomalies du Developpement, |
RCV001526604 | SCV001737033 | pathogenic | Hearing impairment | criteria provided, single submitter | clinical testing | ||
Laboratory of Molecular Genetics |
RCV001829879 | SCV004101246 | pathogenic | Usher syndrome type 2A | 2022-09-06 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003446334 | SCV004172178 | pathogenic | Retinitis pigmentosa 39 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001829879 | SCV004172180 | pathogenic | Usher syndrome type 2A | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001829879 | SCV002093961 | pathogenic | Usher syndrome type 2A | 2020-02-26 | no assertion criteria provided | clinical testing |